Petter Björquist
Cellartis, a Swedish company founded in 2001, was formed as a spin-off from the University of Gothenburg. From its inception the company has worked on pluripotent stem cells and technologies applied to the search for new drugs, toxicity testing and regenerative medicine. Cellartis has proven expertise in many different areas including:
- controlling stem cell differentiation into liver and heart cells which offer unrivalled performance in toxicity testing applications;
- ownership and exploitation of the world's largest stem cell bank (30 proprietary lines);
- effective industrial rollout of their technologies;
- alongside leading partners, involvement in regenerative medicine programs which use the immense potential of stem cells for the restoration of damaged tissues and organs.
The Cellectis stem cells Business Unit has ambitious objectives.
- To industrialize pluripotent stem cells;
- To develop industrial in vitro tools predictive of human physiology and genetic diversity, such as tools for the drug and cosmetic industries, as well as for research, and that can be immediately used in industrial molecular screening and selection processes;
- To develop major partnerships, particularly in the field of regenerative medicine;
- To take a strategic industrial role in order to set standards in an emerging market, forge a strong pioneering position in the areas of focus, and build a genuine industrial sector based around stem cells and a competitive industrial cluster.
Cellectis
VP Regenerative Medicine, Senior Principal Scientist
Ulf Boberg
NovaHep was founded in 2005 on the basis of research conducted at the Huddinge unit of the Karolinska Institute in Stockholm. The company is now based in Gothenburg, Sweden, at the Biotech Center.
NovaHep is active within the field of regenerative medicine, developing stem cell technology with a wide range of applications.
The main area of focus is the production of biological, individualised vessels, in collaboration with the University of Gothenburg. The vessels can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The product is unique and patented. Through an improved alternative to traditional treatments, NovaHep will deliver a life changing impact to patients and provide for major benefits for hospitals, healthcare providers and society – globally.
NovaHep also works with liver stem cells for the purpose of developing a system in which drugs can be tested without the use of laboratory animals.
NovaHep AB
Consultant
Mr Karl Branzen
Life Science Foresight Institute is a research institute formed to assist companies and organisations in the Life Science sector with business intelligence and futures studies.
The institute will provide client organisations with knowledge to facilitate their strategic decision-making – enabling them from the very start to hit the mark on everything from major investments in healthcare infrastructure to product development within a small enterprise.
Life Science Foresight Institute
Senior Analyst
Dr Lars-Erik Briggner
Experts in all areas related to solid state characterization of pharmaceutical material. Unique knowledge related to development of Dry Powder Inhalation products, but cover also oral product development area.
Adroit Science AB
Project Manager
Adam Bruce
TikoMed is a specialty biopharmaceutical company founded in a cradle of fierce entrepreneurship, cutting edge science and industrial competence.
"TikoMed is developing and commercializing life-saving products for severe diseases"
We apply advances in innate immunology to identify mechanisms and develop new products.
Our mission is to develop and commercialize innovative treatments for severe and life-threatening diseases, for the benefit of patients, who lack satisfactory treatment options.
TikoMed
Founder, Boardmember and Business Development
Responsive Web Design powered by 